Movatterモバイル変換


[0]ホーム

URL:


Jump to content
WikipediaThe Free Encyclopedia
Search

Quinestrol

From Wikipedia, the free encyclopedia
Pharmaceutical drug
Pharmaceutical compound
Quinestrol
Clinical data
Trade namesEstrovis, others
Other namesQuinoestrol; Quinestrenol; Quinoestrenol; Ethinylestradiol 3-cyclopentyl ether; EECPE; EE2CPE; W-3566; 3-(Cyclopentyloxy)-17α-ethynylestra-1,3,5(10)-trien-17β-ol
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration
By mouth
Drug classEstrogen;Estrogen ether
ATC code
  • None
Pharmacokinetic data
Eliminationhalf-life>120 hours (>5 days)[1]
Identifiers
  • (8R,9S,13S,14S,17R)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-ol
CAS Number
PubChemCID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard(EPA)
ECHA InfoCard100.005.277Edit this at Wikidata
Chemical and physical data
FormulaC25H32O2
Molar mass364.529 g·mol−1
3D model (JSmol)
  • O(c1ccc2c(c1)CC[C@H]3[C@@H]4CC[C@](C#C)(O)[C@@]4(C)CC[C@H]23)C5CCCC5
  • InChI=1S/C25H32O2/c1-3-25(26)15-13-23-22-10-8-17-16-19(27-18-6-4-5-7-18)9-11-20(17)21(22)12-14-24(23,25)2/h1,9,11,16,18,21-23,26H,4-8,10,12-15H2,2H3/t21-,22-,23+,24+,25+/m1/s1 checkY
  • Key:PWZUUYSISTUNDW-VAFBSOEGSA-N checkY
  (verify)

Quinestrol, also known asethinylestradiol cyclopentyl ether (EECPE), sold under the brand nameEstrovis among others, is anestrogen medication which has been used inmenopausal hormone therapy,hormonal birth control, and to treatbreast cancer andprostate cancer.[2][3] It is taken once per week to once per monthby mouth.[4][5][6][7]

Medical uses

[edit]

Quinestrol has been used as the estrogen component inmenopausal hormone therapy and incombined hormonal birth control.[2][3] It has also occasionally been used in the treatment ofbreast cancer andprostate cancer, as well as to suppresslactation.[2][3][8] On its own as an estrogen, quinestrol was taken once per weekby mouth.[4] As acombined birth control pill, it was used together withquingestanol acetate and was taken once per month by mouth.[5][6][7]

Pharmacology

[edit]
Ethinylestradiol (EE), theactive form of quinestrol.

Quinestrol is aprodrug ofethinylestradiol (EE), with no estrogenic activity of its own.[3][9][10] It is takenorally and has prolonged activity following a single dose,[9][10] with a very longbiological half-life of more than 120 hours (5 days) due to enhancedlipophilicity and storage infat.[3][1] Because of its much longer half-life, quinestrol is two to three times as potent as EE.[3] Also because of its long half-life, quinestrol can be taken once a week or once a month.[3][4][5][6][7]

Following administration, quinestrol is absorbed via thelymphatic system, is stored inadipose tissue, and is gradually released from adipose tissue.[11]

Affinities and estrogenic potencies of estrogen esters and ethers at the estrogen receptors
EstrogenOther namesRBATooltip Relative binding affinity (%)aREP (%)b
ERERαERβ
EstradiolE2100100100
Estradiol 3-sulfateE2S; E2-3S?0.020.04
Estradiol 3-glucuronideE2-3G?0.020.09
Estradiol 17β-glucuronideE2-17G?0.0020.0002
Estradiol benzoateEB; Estradiol 3-benzoate101.10.52
Estradiol 17β-acetateE2-17A31–4524?
Estradiol diacetateEDA; Estradiol 3,17β-diacetate?0.79?
Estradiol propionateEP; Estradiol 17β-propionate19–262.6?
Estradiol valerateEV; Estradiol 17β-valerate2–110.04–21?
Estradiol cypionateEC; Estradiol 17β-cypionate?c4.0?
Estradiol palmitateEstradiol 17β-palmitate0??
Estradiol stearateEstradiol 17β-stearate0??
EstroneE1; 17-Ketoestradiol115.3–3814
Estrone sulfateE1S; Estrone 3-sulfate20.0040.002
Estrone glucuronideE1G; Estrone 3-glucuronide?<0.0010.0006
EthinylestradiolEE; 17α-Ethynylestradiol10017–150129
MestranolEE 3-methyl ether11.3–8.20.16
QuinestrolEE 3-cyclopentyl ether?0.37?
Footnotes:a =Relative binding affinities (RBAs) were determined viain-vitro displacement oflabeledestradiol fromestrogen receptors (ERs) generally ofrodentuterinecytosol.Estrogen esters are variablyhydrolyzed into estrogens in these systems (shorter ester chain length -> greater rate of hydrolysis) and the ER RBAs of the esters decrease strongly when hydrolysis is prevented.b = Relative estrogenic potencies (REPs) were calculated fromhalf-maximal effective concentrations (EC50) that were determined viain-vitroβ‐galactosidase (β-gal) andgreen fluorescent protein (GFP)productionassays inyeast expressing humanERα and humanERβ. Bothmammaliancells and yeast have the capacity to hydrolyze estrogen esters.c = The affinities ofestradiol cypionate for the ERs are similar to those ofestradiol valerate andestradiol benzoate (figure).Sources: See template page.
Potencies of oral estrogens[data sources 1]
CompoundDosage for specific uses (mg usually)[a]
ETD[b]EPD[b]MSD[b]MSD[c]OID[c]TSD[c]
Estradiol (non-micronized)30≥120–3001206--
Estradiol (micronized)6–1260–8014–421–2>5>8
Estradiol valerate6–1260–8014–421–2->8
Estradiol benzoate-60–140----
Estriol≥20120–150[d]28–1261–6>5-
Estriol succinate-140–150[d]28–1262–6--
Estrone sulfate1260422--
Conjugated estrogens5–1260–808.4–250.625–1.25>3.757.5
Ethinylestradiol200 μg1–2280 μg20–40 μg100 μg100 μg
Mestranol300 μg1.5–3.0300–600 μg25–30 μg>80 μg-
Quinestrol300 μg2–4500 μg25–50 μg--
Methylestradiol-2----
Diethylstilbestrol2.520–30110.5–2.0>53
DES dipropionate-15–30----
Dienestrol530–40420.5–4.0--
Dienestrol diacetate3–530–60----
Hexestrol-70–110----
Chlorotrianisene->100-->48-
Methallenestril-400----
Sources and footnotes:
  1. ^Dosages are given in milligrams unless otherwise noted.
  2. ^abcDosed every 2 to 3 weeks
  3. ^abcDosed daily
  4. ^abIn divided doses, 3x/day; irregular and atypical proliferation.

Chemistry

[edit]
See also:List of estrogens § Estradiol derivatives, andList of estrogen esters § Ethers of steroidal estrogens

Quinestrol, also known as ethinylestradiol 3-cyclopentyl ether (EE2CPE), is asyntheticestranesteroid and aderivative ofestradiol.[31][32] It is anestrogen ether, specifically the C3cyclopentylether ofethinylestradiol (17α-ethynylestradiol).[31][32] Closely related estrogens includemestranol (ethinylestradiol 3-methyl ether) andethinylestradiol sulfonate (EES; Turisteron; ethinylestradiol 3-isopropylsulfonate).[31][32]

History

[edit]

Quinestrol was developed and introduced for medical use in the 1960s.[33]

Society and culture

[edit]

Generic names

[edit]

Quinestrol is thegeneric name of the drug and itsINNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name, andBANTooltip British Approved Name.[31][32][34][35] It is also known by its former developmental code nameW-3566.[31][32][34][35]

Brand names

[edit]

Quinestrol has been marketed under brand names including Agalacto-Quilea, Basaquines, Eston, Estrovis, Estrovister, Plestrovis, Qui-Lea, Soluna, and Yueketing, among others.[31][32][34][35]

Availability

[edit]

Quinestrol was marketed asEstrovis in theUnited States byParke-Davis and asQui-Lea inArgentina,[32] but is reportedly not currently marketed.[3] However, it does appear to still be available as anoral contraceptive in combination withprogestins in Argentina andChina.[35]

One tablet form available in China consists of 6 mg levonorgestrel and 3 mg quinestrol; it is used as a prescription "long-term" oral contraceptive, with one dose taken each month.[35][36] It is sold under various brand names including Yuèkětíng (Chinese:悦可婷) and Àiyuè (Chinese:艾悦). A version with the racemicnorgestrel in place of levonorgestrel also appears to be available.[35]

Veterinary use

[edit]

Rodents

[edit]

The Chinese levonorgestrel/quinestrol 2:1 formula is known as EP-1 in veterinary practice. It is known to have some organ-specific effects on theMongolian gerbil as measured by receptor mRNA expression.[37] Incorporated into baits at a concentration of 50 ppm, EP-1 has been used to control wild Mongolian gerbil populations with some success.[38]

References

[edit]
  1. ^abSitruk-Ware R (6 December 2012)."Pharmacology of Different Administration Routes-Oral vs Transdermal.". In Oettel M, Schillinger E (eds.).Estrogens and Antiestrogens II: Pharmacology and Clinical Application of Estrogens and Antiestrogen. Handbook of Experimental Pharmacology. Vol. 135 / 2. Springer Science & Business Media. pp. 248–.doi:10.1007/978-3-642-60107-1_14.ISBN 978-3-642-60107-1.
  2. ^abcZink C (1 January 1988)."Quinestrol".Dictionary of Obstetrics and Gynecology. Walter de Gruyter. pp. 204–.ISBN 978-3-11-085727-6.
  3. ^abcdefghPeterson CM, Udoff LC (1 June 1999)."Primary and secondary hypogonadism in women.". In Meikle AW (ed.).Hormone Replacement Therapy. Springer Science & Business Media. pp. 381–.ISBN 978-1-59259-700-0.
  4. ^abcQuirk Jr JG, Wendel Jr GD (6 December 2012)."Biologic effects of natural and synthetic estrogens.". In Buchsbaum HJ (ed.).The Menopause. Springer Science & Business Media. pp. 60–.ISBN 978-1-4612-5525-3.
  5. ^abcHorsky (6 December 2012)."Contraception". In Horsky J, Presl J (eds.).Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 85, 358, 367.ISBN 978-94-009-8195-9.
  6. ^abcHawkins DF, Elder MG (22 October 2013)."Other Hormal Contraception Procedures".Human Fertility Control: Theory and Practice. Elsevier Science. pp. 92–94.ISBN 978-1-4831-6361-1.
  7. ^abcBennett JP (18 June 1974).Chemical Contraception. Macmillan International Higher Education. pp. 61–.ISBN 978-1-349-02287-8.
  8. ^Vorherr H (2 December 2012).The Breast: Morphology, Physiology, and Lactation. Elsevier Science. pp. 201–203.ISBN 978-0-323-15726-1.
  9. ^abEpstein JA (1967). "Prolonged menstrual response of patients with gonadal failure following quinestrol administration".International Journal of Fertility.12 (2):181–186.PMID 6033895.
  10. ^abGiannina T, Meli A (April 1969). "Prolonged oestrogenic activity in rats after single oral administration of ethinyloestradiol-3-cyclopentyl ether".The Journal of Pharmacy and Pharmacology.21 (4):271–272.doi:10.1111/j.2042-7158.1969.tb08247.x.PMID 4390151.S2CID 19407816.
  11. ^Hammond CB, Maxson WS (January 1982). "Current status of estrogen therapy for the menopause".Fertility and Sterility.37 (1):5–25.doi:10.1016/S0015-0282(16)45970-4.PMID 6277697.
  12. ^Lauritzen C (September 1990). "Clinical use of oestrogens and progestogens".Maturitas.12 (3):199–214.doi:10.1016/0378-5122(90)90004-P.PMID 2215269.
  13. ^Lauritzen C (June 1977). "[Estrogen thearpy in practice. 3. Estrogen preparations and combination preparations]" [Estrogen therapy in practice. 3. Estrogen preparations and combination preparations].Fortschritte Der Medizin (in German).95 (21):1388–92.PMID 559617.
  14. ^Wolf AS, Schneider HP (12 March 2013).Östrogene in Diagnostik und Therapie. Springer-Verlag. pp. 78–.ISBN 978-3-642-75101-1.
  15. ^Göretzlehner G, Lauritzen C, Römer T, Rossmanith W (1 January 2012).Praktische Hormontherapie in der Gynäkologie. Walter de Gruyter. pp. 44–.ISBN 978-3-11-024568-4.
  16. ^Knörr K, Beller FK, Lauritzen C (17 April 2013).Lehrbuch der Gynäkologie. Springer-Verlag. pp. 212–213.ISBN 978-3-662-00942-0.
  17. ^Horský J, Presl J (1981)."Hormonal Treatment of Disorders of the Menstrual Cycle". In Horsky J, Presl J (eds.).Ovarian Function and its Disorders: Diagnosis and Therapy. Springer Science & Business Media. pp. 309–332.doi:10.1007/978-94-009-8195-9_11.ISBN 978-94-009-8195-9.
  18. ^Pschyrembel W (1968).Praktische Gynäkologie: für Studierende und Ärzte. Walter de Gruyter. pp. 598–599.ISBN 978-3-11-150424-7.
  19. ^Lauritzen CH (January 1976). "The female climacteric syndrome: significance, problems, treatment".Acta Obstetricia Et Gynecologica Scandinavica. Supplement.51:47–61.doi:10.3109/00016347509156433.PMID 779393.
  20. ^Lauritzen C (1975). "The Female Climacteric Syndrome: Significance, Problems, Treatment".Acta Obstetricia et Gynecologica Scandinavica.54 (s51):48–61.doi:10.3109/00016347509156433.ISSN 0001-6349.
  21. ^Kopera H (1991). "Hormone der Gonaden".Hormonelle Therapie für die Frau. Kliniktaschenbücher. pp. 59–124.doi:10.1007/978-3-642-95670-6_6.ISBN 978-3-540-54554-5.ISSN 0172-777X.
  22. ^Scott WW, Menon M, Walsh PC (April 1980). "Hormonal Therapy of Prostatic Cancer".Cancer.45 (Suppl 7):1929–1936.doi:10.1002/cncr.1980.45.s7.1929.PMID 29603164.
  23. ^Leinung MC, Feustel PJ, Joseph J (2018)."Hormonal Treatment of Transgender Women with Oral Estradiol".Transgender Health.3 (1):74–81.doi:10.1089/trgh.2017.0035.PMC 5944393.PMID 29756046.
  24. ^Ryden AB (1950). "Natural and synthetic oestrogenic substances; their relative effectiveness when administered orally".Acta Endocrinologica.4 (2):121–39.doi:10.1530/acta.0.0040121.PMID 15432047.
  25. ^Ryden AB (1951). "The effectiveness of natural and synthetic oestrogenic substances in women".Acta Endocrinologica.8 (2):175–91.doi:10.1530/acta.0.0080175.PMID 14902290.
  26. ^Kottmeier HL (1947). "Ueber blutungen in der menopause: Speziell der klinischen bedeutung eines endometriums mit zeichen hormonaler beeinflussung: Part I".Acta Obstetricia et Gynecologica Scandinavica.27 (s6):1–121.doi:10.3109/00016344709154486.ISSN 0001-6349.There is no doubt that the conversion of the endometrium with injections of both synthetic and native estrogenic hormone preparations succeeds, but the opinion whether native, orally administered preparations can produce a proliferation mucosa changes with different authors. PEDERSEN-BJERGAARD (1939) was able to show that 90% of the folliculin taken up in the blood of the vena portae is inactivated in the liver. Neither KAUFMANN (1933, 1935), RAUSCHER (1939, 1942) nor HERRNBERGER (1941) succeeded in bringing a castration endometrium into proliferation using large doses of orally administered preparations of estrone or estradiol. Other results are reported by NEUSTAEDTER (1939), LAUTERWEIN (1940) and FERIN (1941); they succeeded in converting an atrophic castration endometrium into an unambiguous proliferation mucosa with 120–300 oestradiol or with 380 oestrone.
  27. ^Rietbrock N, Staib AH, Loew D (11 March 2013).Klinische Pharmakologie: Arzneitherapie. Springer-Verlag. pp. 426–.ISBN 978-3-642-57636-2.
  28. ^Martinez-Manautou J, Rudel HW (1966). "Antiovulatory Activity of Several Synthetic and Natural Estrogens". In Robert Benjamin Greenblatt (ed.).Ovulation: Stimulation, Suppression, and Detection. Lippincott. pp. 243–253.
  29. ^Herr F, Revesz C, Manson AJ, Jewell JB (1970). "Biological Properties of Estrogen Sulfates".Chemical and Biological Aspects of Steroid Conjugation. pp. 368–408.doi:10.1007/978-3-642-49793-3_8.ISBN 978-3-642-49506-9.
  30. ^Duncan CJ, Kistner RW, Mansell H (October 1956)."Suppression of ovulation by trip-anisyl chloroethylene (TACE)".Obstetrics and Gynecology.8 (4):399–407.PMID 13370006.
  31. ^abcdefElks J (14 November 2014).The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 522–.ISBN 978-1-4757-2085-3.
  32. ^abcdefg"Quinestrol".Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 905–.ISBN 978-3-88763-075-1.
  33. ^Medical Gynaecology and Sociology. Medical and Scientific Services Limited. 1967.[...] J. Fertil., 1967, 12, 2) contains 23 papers presented at a symposium on QUINESTROL. Quinestrol is a newly-developed synthetic steroid, and is the cyclo-pentyl ether of a ethinyl oestradiol.
  34. ^abcMorton IK, Hall JM (6 December 2012).Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 243–.ISBN 978-94-011-4439-1.
  35. ^abcdef"Quinestrol".Drugs.com. Archived fromthe original on 20 October 2015.
  36. ^"悦可婷 左炔诺孕酮炔雌醚片 6片/盒" [Yueketing Levonorgestrel Ethinylestradiol Tablets 6 Pieces/Box].Tmall (in Chinese). Archived fromthe original on 2018-07-16. Retrieved2018-07-16.When taking the medicine for the first time, take the medicine once after lunch on the fifth day counting from the day of menstrual cramps, and take the second medicine at an interval of 20 days. Afterwards, take the second medicine taking day as the monthly medicine taking date, and take one tablet every month. When changing from short-acting oral contraceptives to long-acting contraceptives, you can take one long-acting contraceptive the next day after taking 22 tablets, and then take one tablet every month on the same day you started taking long-acting contraceptives.
  37. ^Lv X, Shi D (January 2012). "Combined effects of levonorgestrel and quinestrol on reproductive hormone levels and receptor expression in females of the Mongolian gerbil (Meriones unguiculatus)".Zoological Science.29 (1):37–42.doi:10.2108/zsj.29.37.PMID 22233494.S2CID 22347486.
  38. ^Fu H, Zhang J, Shi D, Wu X (September 2013). "Effects of levonorgestrel-quinestrol (EP-1) treatment on Mongolian gerbil wild populations: a case study".Integrative Zoology.8 (3):277–284.doi:10.1111/1749-4877.12018.PMID 24020466.
Estrogens
ERTooltip Estrogen receptor agonists
Progonadotropins
Antiestrogens
ERTooltip Estrogen receptor antagonists
(incl.SERMsTooltip selective estrogen receptor modulators/SERDsTooltip selective estrogen receptor downregulators)
Aromatase inhibitors
Antigonadotropins
Others
ERTooltip Estrogen receptor
Agonists
Mixed
(SERMsTooltip Selective estrogen receptor modulators)
Antagonists
GPERTooltip G protein-coupled estrogen receptor
Agonists
Antagonists
Unknown
Retrieved from "https://en.wikipedia.org/w/index.php?title=Quinestrol&oldid=1171005805"
Categories:
Hidden categories:

[8]ページ先頭

©2009-2025 Movatter.jp